Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab Long-term Safety and Efficacy Extension (OSLER-2)
NCT01854918Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2013
- Primary completion
- May 2018
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of evolocumab in hyperlipidemia, mixed dyslipidemia, sponsored by Amgen. Started Apr 2013; status: completed.
02
Drugs
evolocumab
03
Conditions
hyperlipidemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT01854918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01854918.